Hasil Pencarian  ::  Simpan CSV :: Kembali

"This book covers the science and approaches of enzyme inhibition applied in drug discovery and drug development, including both pharmacology and pharmacokinetic aspects of enzyme inhibition. Additionally, the book covers the inhibition of drug metabolizing and disposition enzymes including transporters (mostly "bad" or "undesirable" enzyme inhibition) as well as the inhibition of drug target enzymes (mostly the "good" or "desirable" enzyme inhibition). Each chapter details the basic scientific concepts, experimental approaches, data interpretation, and current challenges and promising advancements for a specific type of inhibition."

"This book contains case studies of the discovery of erythromycin analogs (antibiotics), Tagamet, and Ultiva (remifentanil). Discusses the discovery of agents for the treatment and management of bacterial infections, Parkinson's disease, psoriasis, ulcers and stomach pain, atopic dermatitis, asthma, and cancer. Contains chapters on combinatorial chemistry, molecular biology-based drug discovery, genomics, and chemogenomics.The first volume of this set thoroughly describes conceptualizing a drug, creating a library of candidates for testing, screening those candidates for in vitro and in vivo activity, conducting and analyzing the results of clinical trials, and revising the drug as necessary."

"This handbook provides the first-ever inside view of today's integrated approach to rational drug design. Chemoinformatics experts from large pharmaceutical companies, as well as from chemoinformatics service providers and from academia demonstrate what can be achieved today by harnessing the power of computational methods for the drug discovery process. With the user rather than the developer of chemoinformatics software in mind, this book describes the successful application of computational tools to real-life problems and presents solution strategies to commonly encountered problems. It shows how almost every step of the drug discovery pipeline can be optimized and accelerated by using chemoinformatics tools-from the management of compound databases to targeted combinatorial synthesis, virtual screening and efficient hit-to-lead transition. "

"Born out of a project of the IUPAC's committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending the previously published volume by nine new analog classes and eight case studies. Like its precursor, this volume also contains a general section discussing universally applicable strategies for analog discovery and development. Spanning a wide range of therapeutic fields and chemical classes, the two volumes together constitute the first systematic approach to drug analog development."

"The drug discovery handbook gives professionals a tool to facilitate drug discovery by bringing together, for the first time in one resource, a compendium of methods and techniques that need to be considered when developing new drugs. This comprehensive, practical guide presents an explanation of the latest techniques and methods in drug discovery, including: genomics, proteomics, high-throughput screening, and systems biology; summaries of how these techniques and methods are used to discover new central nervous system agents, antiviral agents, respiratory drugs, oncology drugs, and more; and, specific approaches to drug discovery, including problems that are encountered, solutions to these problems, and limitations of various methods and techniques. "

"The first authoritative overview of past and current strategies for successful drug development by analog generation, this unique resource spans all important drug classes and all major therapeutic fields, including histamine antagonists, ACE inhibitors, beta blockers, opioids, quinolone antibiotics, steroids and anticancer platinum compounds. Of the 19 analog classes presented in detail, 9 are described by the scientists who discoverd them. The book includes a table of the most successful drug analogs as based on the IMS ranking and compares them in terms of chemical structure, mode of action and patentability."